Nuclear medicine physician‐scientist Professor Michael Hofman has pioneered use of novel radioactive molecules that seek out cancer cells for both whole body imaging and also targeted treatment. These new practice changing technologies have been adopted globally including PSMA PET imaging and radioligand therapy, demonstrating greater accuracy than standard imaging, and better outcomes and quality‐of‐life compared to chemotherapy treatment. Professor Hofman has provided leadership in co‐operative clinical trials groups, training and defining practice standards in Australia and internationally.